Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726229 · ClinicalTrials.gov registry record
Cholate Clearance in Fontans
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 50
- Enrollment target
NCT03726229: Completed study, sponsored by University of Pennsylvania.
NCT03726229 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03726229 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
HepQuant is an assay to measure liver function in other forms of liver disease such as hepatitis C. It measures the ability of the liver to process an naturally occurring substance called cholate and has been shown to predict clinical outcomes in some patient populations. The Fontan survivor is a patient who has undergone surgery or a series of surgeries that result in a functional single ventricle. The liver is particularly vulnerable to disease including congestion, fibrosis, and even cirrhosis. Currently liver function in the Fontan is not well-characterized and the HepQuant assay could help answer this question.
Primary Outcome
D4-cholate and 13C-cholate clearance
Interventions
- DEVICE Cholate assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2022-05-25 |
What the finished NCT03726229 record still lists
NCT03726229 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cholate assay is the first listed.
NCT03726229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03726229 about?
NCT03726229 is a clinical study titled "Cholate Clearance in Fontans". HepQuant is an assay to measure liver function in other forms of liver disease such as hepatitis C. It measures the ability of the liver to process an naturally occurring substance called cholate and has been shown to predict clinical outcomes in some patient populations. The Fontan survivor is a p...
What is the current status of trial NCT03726229?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2019-05-01. Estimated completion is 2022-05-25.
What interventions are being tested in trial NCT03726229?
The interventions under investigation include: Cholate assay (DEVICE).
Who is sponsoring clinical trial NCT03726229?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI